Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study
ConclusionTotal cumulative doses of 100 mCi or less of RAI can be safely administered without concerns about second primary malignancy. However, the risk of second primary malignancy increases in a dose-dependent manner, and the risk–benefit needs to be considered for doses over 100 mCi of RAI therapy.
Source: Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Health Insurance | Hematology | Insurance | Nuclear Medicine | Radioiodine Therapy | South Korea Health | Statistics | Study | Thyroid | Thyroid Cancer